Induction of colitis in IL2-deficient-mice: The role of thymic and peripheral dysregulation in the generation of autoreactive T cells

Research in Immunology

Volumn 148, Issue 8-9, 1997, Pages 582-588

  Ehrhardt, R O ^a   Ludviksson, B ^b  

^a PROTEIN DESIGN LABS INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNITY; BACTERIAL COLONIZATION; COLITIS; CYTOKINE PRODUCTION; ENTERITIS; HELICOBACTER; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031253620     PISSN: 09232494     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2494(98)80153-3     Document Type: Article

References (62)

1. [1] Sadlack, B. et al. (1993), Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene [see comments]. Cell, 75(2), 253-261.
2. [2] Kuhn, R. et al. (1993), Interleukin-10-deficient mice develop chronic enterocolitis [see comments]. Cell, 75(2), 263-274.
3. [3] Strober, W. & Ehrhardt, R.O. (1993), Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice [comment]. Cell, 75(2), 203-205.
4. [4] Mombaerts, P. et al. (1993), Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice [see comments]. Cell 75(2), 274-282.
5. [5] Ehrhardt, R.O. et al. (1997), Induction and prevention of colonic inflammation in IL-2-deficient mice. J. Immunol., 158(2), 566-573.
6. [6] Duchmann, R. et al. (1996), Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol., 26(4), 934-938.
7. [7] Rath, H.C. et al. (1996), Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Invest., 98(4), 945-953.
8. [8] Taurog, J.D. et al. (1994), The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med., 180(6), 2359-2364.
9. [9] Aranda, R. et al. (1997), Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J. Immunol., 158(7), 3464-3473.
10. [10] Cahill, R.J. et al. (1997), Inflammatory bowel disease: an immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect. Immun., 65(8), 3126-3131.
11. [11] Pirzer, U. et al. (1991), Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet, 338(8777), 1238-1239.
12. [12] Mayer, L. & Eisenhardt, D. (1990), Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J. Clin. Invest., 86(4), 1255-1260.
13. [13] Segal, B.M., Klinman, D.M. & Shevach, E.M. (1997), Microbial products induce autoimmune disease by an IL-12 dependent pathway. J. Immunol., 158(11), 5087-5090.
14. [14] Trembleau, S. et al. (1995), The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today, 16(8), 383-386.
15. [15] Sartor, R.B. (1994), Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology, 106(2), 533-539.
16. [16] Strober, W. & James, S.P. (1992), The immunopathogenesis of gastrointestinal and hepatobiliary diseases. Jama, 268(20), 2910-2917.
17. [17] Fuss, I.J. et al. (1996), Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease, Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol., 157(3), 1261-1270.
18. [18] Niessner, M. & Volk, B.A. (1995), Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin. Exp. Immunol., 101(3), 428-435.
19. [19] Desreumaux, P. et al. (1997), Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology, 113(1), 118-126.
20. [20] Parronchi, P. et al. (1997), Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol., 150(3), 823-832.
21. [21] Soderstrom, K. et al. (1996), Increased frequency of abnormal gamma delta T cells in blood of patients with inflammatory bowel diseases. J. Immunol., 156(6), 2331-2339.
22. [22] Breese, E. et al. (1993), Interleukin-2-and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology, 78(1), 127-131.
23. [23] Karttunnen, R. et al. (1994), Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J. Clin. Pathol., 47(11), 1015-1018.
24. [24] Mizoguchi, A. et al. (1996), Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J. Exp. Med., 183(3), 847-856.
25. [25] Simpson, S.J. et al. (1995), Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur. J. Immunol., 25(9), 2618-2625.
26. [26] Rudolph, U. et al. (1995), Gi2 alpha protein deficiency: a model of inflammatory bowel disease. J. Clin. Immunol., 15, 101S-105S.
27. [27] Hornquist, C.E. et al. (1997), G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD44+ T cells and proinflammatory Th1-type cytokines. J. Immunol., 158(3), 1068-1077.
28. [28] Simpson, S.J. et al. (1997), Expression of pro-inflammatory cytokines by TCR alpha beta+ and TCR gamma delta+ T cells in an experimental model of colitis. Eur. J. Immunol., 27(1), 17-25.
29. [29] Neurath, M.F. et al. (1995), Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med., 182(5), 1281-1290.
30. [30] Powrie, F., Leach, M.W., Mauze, S., Menon, S., Barcomb Caddle, L. & Coffman, R.L. (1994), Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity, 1, 553-562.
31. [31] Miller, J.F. & Flavell, R.A. (1994), T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance. Curr. Opin. Immunol., 6(6), 892-899.
32. [32] Sprent, J. (1993), The thymus and T-cell tolerance. Ann. NY Acad. Sci., 681, 5-15.
33. [33] Lowenthal, J.W., Corhesy, P., Tougne, C., Lees, R., MacDonald, H.R. & Nabholz, M. (1985), High and low affinity IL-2 receptors:analysis by IL-2 dissociation rate and reactivity with monoclonal antireceptor antibody, Pc61. J. Immunol., 135, 3988.
34. [34] Robb, R.J., Greene, W.C. & Rusk, C.M. (1984), Low and high affinity cellular receptors for interleukin 2. Implication for the level of Tac antigen. J. Exp. Med., 160, 1126.
35. [35] Smith, K.A. (1980), T cell growth factor. Immunol. Rev., 51, 337.
36. [36] Skinner, M. & Marbrook, J. (1988), Effect of interleukin 2 on fetal thymocytes in organ cultures: generation of lymphokine-activated killer cells. Cell. Immunol., 112(1), 104-111.
37. [37] Raulet, D.H. (1985), Expression and function of interleukin-2 receptors on immature thymocytes. Nature, 314, 101.
38. [38] Ceredig, R., Lowenthal, J.W., Nabholz, M. & MacDonald, H.R. (1985), Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature, 314, 98.
39. [39] De la Hera, A., Toribio, M.L., Marquez, C. & Martinez, C. (1985), Interleukin 2 promotes growth and cytolytic activity in human 73+4-8-thymocytes. Proc. Natl. Acad. Sci. USA, 82(18), 6268-6271.
40. [40] Toribio, M.L., Gutierrez-Ramos, J.C., Pezzi, L., Marcos, M.A. & Martinez, C. (1989), Interleukin-2-dependent autocrine proliferation in T-cell development. Nature, 342(6245), 82-85.
41. [41] Hanke, T., Mitnacht, R., Boyd, R. & Hunig, T. (1994), Induction of interleukin 2 receptor beta chain expression by self-recognition in the thymus. J. Exp. Med., 180(5), 1629-1636.
42. [42] Ludviksson, B.R., Gray, B., Strober, W. & Ehrhardt, R.O. (1997), Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes. J. Immunol., 158(1), 104-111.
43. [43] Groux, H., Monte, D., Plouvier, B., Capron, A. & Ameisen, J.C. (1993), CD3-mediated apoptosis of human medullary thymocytes and activated peripheral T cells: respective roles of interleukin-1, interleukin-2, interferon-gamma and accessory cells. Eur. J. Immunol., 23(7), 1623-1629.
44. [44] Godfrey, D.I., Kennedy, J., Gately, M.K., Hakimi, J., Hubbard, B.R. & Zlotnik, A. (1994), IL-12 influences intrathymic T cell development. J. Immunol., 152(6), 2729-2735.
45. [45] Krämer, S., Schimpl, A. & Hünig, T. (1995), Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J. Exp. Med., 182, 1769-1776.
46. [46] Hollander, G.A., Simpson, S.J., Mizoguchi, E., Nichogiannopoulou, A., She, J., Gutierrez-Ramos, J.C., Bhan, A.K., Burakoff, S.J., Wang, B. & Terhorst C. (1995), Severe colitis in mice with aberrant thymic selection. Immunity, 3(1), 27-38.
47. [47] Rudolph, U., Finegold, M.J., Rich, S.S., Harriman, G.R., Srinivasan, Y., Brabet, P., Bradley, A. & Birnbaumer, L. (1995), Gi2 alpha protein deficiency: a model of inflammatory bowel disease. J. Clin. Immunol., 15, 101S-105S.
48. [48] Kretz-Rommel, A., Duncan, S.R. & Rubin, R.L. (1997), Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. J. Clin. Invest., 99(8), 1888-1896.
49. [49] Duchmann, R. et al. (1995), Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) [see comments]. Clin. Exp. Immunol., 102(3), 448-455.
50. [50] Macpherson, A. et al. (1996), Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut, 38(3), 365-375.
51. [51] Khoo, U.Y., Proctor, I.E. & Macpherson, A.J. (1997), CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens. J. Immunol., 158(8), 3626-3634.
52. [52] Lenardo, M.J. (1991), Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature, 353(6347), 858-861.
53. [53] Matsuura, T. et al. (1993), Immune activation genes in inflammatory bowel disease. Gastroenterology, 104(2), 448-458.
54. [54] Kusugami, K. et al. (1991), Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology, 101(6), 1594-1605.
55. [55] Ludviksson, B.R., Ehrhardt, R.O. & Strober, W. (1997), TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J. Immunol., 159(7), 3622-3628.
56. [56] Neurath, M.F. et al. (1996), Experimental granulomatous colitis in mice is abrogated by induction-beta-mediated oral tolerance. J. Exp. Med., 183(6), 2605-2616.
57. [57] Elson, C.O. et al. (1996), Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J. Immunol., 157(5), 2174-2185.
58. [58] Powrie, F. et al. (1996), A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J. Exp. Med., 183(6), 2669-2674.
59. [59] Targan, S.R. et al. (1997), A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med., 337(15), 1029-1035.
60. [60] Sandborn, W.J. (1997), A controlled trial of antitumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology, 113(3), 1042-1043.
61. [61] Van Deventer, S.J. & Camoglio, L. (1997), Monoclonal antibody therapy of inflammatory bowel disease. Pharm. World Sci., 19(2), 55-59.
62. [62] Stack, W.A. et al. (1997). Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease [see comments]. Lancet, 349(9051), 521-524.